Responses
Regular and Young Investigator Award Abstracts
Clinical Trials In Progress
783 Trial in progress: a phase 1/2 open-label study (IOV-GM1–201) of TALEN-mediated PD-1–inactivated autologous tumor-infiltrating lymphocytes (TIL; IOV-4001) in patients with advanced melanoma and NSCLC
Compose a Response to This Article
Other responses
No responses have been published for this article.